ees Europe: Battery Storage – Powerbanks for the Energy Transition
4.6.2024 15:49:00 EEST | Business Wire | Press release
Battery storage is booming. According to a study by Frontier Economics, the volume of grid-connected storage in Germany alone could increase to 60 gigawatts (GW) or 271 gigawatt-hours (GWh) by 2050. This is forty times the current storage capacity. Similar dynamics in cost reduction and installation speed are expected as seen with photovoltaics (PV) in recent years. Soon, battery storage will fundamentally change energy supply. The latest technologies, trends, and market developments will be showcased at ees Europe, Europe’s largest and most international exhibition for batteries and energy storage systems. It will take place from June 19 to 21 as part of The smarter E Europe, Europe’s largest alliance of exhibitions for the energy industry, in Munich. Around 3,000 exhibitors and over 115,000 visitors from around the world are expected in 19 exhibition halls and an outdoor area.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604806032/en/
Innovations in the field of large-scale storage can be seen at this year’s ees Europe. (Photo: Business Wire)
The growth of grid-connected storage brings enormous advantages to the energy system and offers economic benefits. The expansion of large-scale storage can significantly reduce the need for new gas power plant investments in Germany by up to 9 GW. This expansion also contributes significantly to reducing CO2 emissions. The key point: this growth is purely market-driven and does not rely on government subsidies.
Short-term storage enables system transformation
Battery storage increasingly assumes critical roles in ensuring a reliable power supply and stabilizing power grids. Large battery storage systems ensure voltage control, provide immediate reserve capacity, and facilitate black start capability, playing a part in congestion management. They can balance fluctuations in the grid within seconds and store energy for hours or days. The black start capability of storage systems is crucial in emergencies.
Moreover, storage systems can mitigate the effects of delayed grid expansion. They help optimize the utilization of the limited grid infrastructure, allowing more facilities to be connected. This enables more capacity and additional PV installations despite limited grid connection capacity. Another benefit: battery storage increases the market value of renewable energy. Green electricity can be stored when market prices are low and fed into the grid when demand is high and electricity prices are correspondingly high.
International storage revolution
Worldwide, exponential growth in battery storage is evident. Experts predict that global production capacity will rise to 500 GWh per year by 2025. In markets such as Australia, the USA, and India, tenders for new wind or solar capacities have been coupled with storage for years. In Germany, the speed of expansion and the installed storage capacity are still modest. However, this year, battery storage systems in Germany will surpass pumped storage systems in installed capacity for the first time.
Setting the right framework
To make stationary storage of all sizes attractive, a favorable market environment and simple regulations are needed. Market-driven expansion must continue to be enabled and improved. Modern framework conditions for battery storage should be set through reforms in grid fees, flexible electricity tariffs, or the introduction of contracts for difference.
ees Europe
Every year, ees Europe, Europe’s largest and most international exhibition for batteries and energy storage systems, provides a networking opportunity for the industry’s key players – all under the motto “Innovating Energy Storage”. It focuses on the latest technologies, trends and market developments. ees Europe will take place from June 19–21, 2024 as part of The smarter E Europe at Messe München.
For more information: www.ees-europe.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604806032/en/
Contact information
ressourcenmangel an der Panke GmbH
Roberto Freiberger
roberto.freiberger@ressourcenmangel.de
Solar Promotion GmbH
Peggy Zilay
zilay@solarpromotion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom